APO Research
Talk to an analyst

APO RESEARCH · REPORT

Choroidal Neovascularization Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026

19 December 2025207 pages

Choose your research edition.

Industry ResearchChoroidal Neovascularization Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Choroidal Neovascularization Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Choroidal Neovascularization Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Choroidal Neovascularization Drug market include Eli Lilly and Company, Soligenix, Inc., RxBio, Inc., RedHill Biopharma Ltd., RDD Pharma Ltd., ProCertus BioPharm Inc., Pluristem Therapeutics Inc., PharmaIN Corporation and Onconova Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Choroidal Neovascularization Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Choroidal Neovascularization Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Choroidal Neovascularization Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Choroidal Neovascularization Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Choroidal Neovascularization Drug Segment by Company

Eli Lilly and Company

Soligenix, Inc.

RxBio, Inc.

RedHill Biopharma Ltd.

RDD Pharma Ltd.

ProCertus BioPharm Inc.

Pluristem Therapeutics Inc.

PharmaIN Corporation

Onconova Therapeutics, Inc.

Neumedicines Inc.

Meabco A/S

INSYS Therapeutics, Inc.

Humanetics Corporation

GNI Group Ltd.

Diffusion Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Cleveland BioLabs, Inc.

Chrysalis BioTherapeutics, Inc.

Cellphire, Inc.

Choroidal Neovascularization Drug Segment by Type

EWA-001

Entolimod

DG-3

BBT-007

BB-3

AVMOC-001

Others

Choroidal Neovascularization Drug Segment by Application

Clinic

Hospital

Others

Choroidal Neovascularization Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Choroidal Neovascularization Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Choroidal Neovascularization Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Choroidal Neovascularization Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Choroidal Neovascularization Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Choroidal Neovascularization Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Choroidal Neovascularization Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Choroidal Neovascularization Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Choroidal Neovascularization Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Choroidal Neovascularization Drug industry.

Chapter 3: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Choroidal Neovascularization Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Choroidal Neovascularization Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Choroidal Neovascularization Drug Industry Trends Table 2. Choroidal Neovascularization Drug Industry Drivers Table 3. Choroidal Neovascularization Drug Industry Opportunities and Challenges Table 4. Choroidal Neovascularization Drug Industry Restraints Table 5. Global Choroidal Neovascularization Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Choroidal Neovascularization Drug Revenue Share by Company (2021-2026) Table 7. Global Choroidal Neovascularization Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Choroidal Neovascularization Drug Sales Volume Share by Company (2021-2026) Table 9. Global Choroidal Neovascularization Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Choroidal Neovascularization Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Choroidal Neovascularization Drug Key Company Manufacturing Base & Headquarters Table 12. Global Choroidal Neovascularization Drug Company, Product Type & Application Table 13. Global Choroidal Neovascularization Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Choroidal Neovascularization Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of EWA-001 Table 18. Significant Companies of Entolimod Table 19. Significant Companies of DG-3 Table 20. Significant Companies of BBT-007 Table 21. Significant Companies of BB-3 Table 22. Significant Companies of AVMOC-001 Table 23. Significant Companies of Others Table 24. Global Choroidal Neovascularization Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Choroidal Neovascularization Drug Sales Volume by Type (2021-2026) & (K Units) Table 26. Global Choroidal Neovascularization Drug Sales Volume by Type (2027-2032) & (K Units) Table 27. Global Choroidal Neovascularization Drug Sales Volume Share by Type (2021-2026) Table 28. Global Choroidal Neovascularization Drug Sales Volume Share by Type (2027-2032) Table 29. Global Choroidal Neovascularization Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Choroidal Neovascularization Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Choroidal Neovascularization Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Choroidal Neovascularization Drug Sales Value Share by Type (2021-2026) Table 33. Global Choroidal Neovascularization Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of Others Table 37. Global Choroidal Neovascularization Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Choroidal Neovascularization Drug Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Choroidal Neovascularization Drug Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Choroidal Neovascularization Drug Sales Volume Share by Application (2021-2026) Table 41. Global Choroidal Neovascularization Drug Sales Volume Share by Application (2027-2032) Table 42. Global Choroidal Neovascularization Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Choroidal Neovascularization Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Choroidal Neovascularization Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Choroidal Neovascularization Drug Sales Value Share by Application (2021-2026) Table 46. Global Choroidal Neovascularization Drug Sales Value Share by Application (2027-2032) Table 47. Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Units) Table 49. Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2026) Table 50. Global Choroidal Neovascularization Drug Sales by Region (2027-2032) & (K Units) Table 51. Global Choroidal Neovascularization Drug Sales Market Share by Region (2027-2032) Table 52. Global Choroidal Neovascularization Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Choroidal Neovascularization Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Choroidal Neovascularization Drug Sales Value Share by Region (2021-2026) Table 55. Global Choroidal Neovascularization Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Choroidal Neovascularization Drug Sales Value Share by Region (2027-2032) Table 57. Global Choroidal Neovascularization Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Choroidal Neovascularization Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Choroidal Neovascularization Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 62. Global Choroidal Neovascularization Drug Sales Market Share by Country (2021-2026) Table 63. Global Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 64. Global Choroidal Neovascularization Drug Sales Market Share by Country (2027-2032) Table 65. Global Choroidal Neovascularization Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Choroidal Neovascularization Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Choroidal Neovascularization Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Choroidal Neovascularization Drug Sales Value Market Share by Country (2027-2032) Table 69. Eli Lilly and Company Company Information Table 70. Eli Lilly and Company Business Overview Table 71. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio Table 73. Eli Lilly and Company Recent Development Table 74. Soligenix, Inc. Company Information Table 75. Soligenix, Inc. Business Overview Table 76. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio Table 78. Soligenix, Inc. Recent Development Table 79. RxBio, Inc. Company Information Table 80. RxBio, Inc. Business Overview Table 81. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio Table 83. RxBio, Inc. Recent Development Table 84. RedHill Biopharma Ltd. Company Information Table 85. RedHill Biopharma Ltd. Business Overview Table 86. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 88. RedHill Biopharma Ltd. Recent Development Table 89. RDD Pharma Ltd. Company Information Table 90. RDD Pharma Ltd. Business Overview Table 91. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 93. RDD Pharma Ltd. Recent Development Table 94. ProCertus BioPharm Inc. Company Information Table 95. ProCertus BioPharm Inc. Business Overview Table 96. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio Table 98. ProCertus BioPharm Inc. Recent Development Table 99. Pluristem Therapeutics Inc. Company Information Table 100. Pluristem Therapeutics Inc. Business Overview Table 101. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio Table 103. Pluristem Therapeutics Inc. Recent Development Table 104. PharmaIN Corporation Company Information Table 105. PharmaIN Corporation Business Overview Table 106. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio Table 108. PharmaIN Corporation Recent Development Table 109. Onconova Therapeutics, Inc. Company Information Table 110. Onconova Therapeutics, Inc. Business Overview Table 111. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 113. Onconova Therapeutics, Inc. Recent Development Table 114. Neumedicines Inc. Company Information Table 115. Neumedicines Inc. Business Overview Table 116. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio Table 118. Neumedicines Inc. Recent Development Table 119. Meabco A/S Company Information Table 120. Meabco A/S Business Overview Table 121. Meabco A/S Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Meabco A/S Choroidal Neovascularization Drug Product Portfolio Table 123. Meabco A/S Recent Development Table 124. INSYS Therapeutics, Inc. Company Information Table 125. INSYS Therapeutics, Inc. Business Overview Table 126. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 128. INSYS Therapeutics, Inc. Recent Development Table 129. Humanetics Corporation Company Information Table 130. Humanetics Corporation Business Overview Table 131. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio Table 133. Humanetics Corporation Recent Development Table 134. GNI Group Ltd. Company Information Table 135. GNI Group Ltd. Business Overview Table 136. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio Table 138. GNI Group Ltd. Recent Development Table 139. Diffusion Pharmaceuticals Inc. Company Information Table 140. Diffusion Pharmaceuticals Inc. Business Overview Table 141. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio Table 143. Diffusion Pharmaceuticals Inc. Recent Development Table 144. Cumberland Pharmaceuticals, Inc. Company Information Table 145. Cumberland Pharmaceuticals, Inc. Business Overview Table 146. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio Table 148. Cumberland Pharmaceuticals, Inc. Recent Development Table 149. Cleveland BioLabs, Inc. Company Information Table 150. Cleveland BioLabs, Inc. Business Overview Table 151. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio Table 153. Cleveland BioLabs, Inc. Recent Development Table 154. Chrysalis BioTherapeutics, Inc. Company Information Table 155. Chrysalis BioTherapeutics, Inc. Business Overview Table 156. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 158. Chrysalis BioTherapeutics, Inc. Recent Development Table 159. Cellphire, Inc. Company Information Table 160. Cellphire, Inc. Business Overview Table 161. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio Table 163. Cellphire, Inc. Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Choroidal Neovascularization Drug Distributors List Table 167. Choroidal Neovascularization Drug Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Choroidal Neovascularization Drug Product Image Figure 2. Global Choroidal Neovascularization Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Choroidal Neovascularization Drug Sales (2021-2032) & (K Units) Figure 5. Global Choroidal Neovascularization Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Choroidal Neovascularization Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. EWA-001 Image Figure 10. Entolimod Image Figure 11. DG-3 Image Figure 12. BBT-007 Image Figure 13. BB-3 Image Figure 14. AVMOC-001 Image Figure 15. Others Image Figure 16. Global Choroidal Neovascularization Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Choroidal Neovascularization Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Choroidal Neovascularization Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Choroidal Neovascularization Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Choroidal Neovascularization Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Choroidal Neovascularization Drug Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Others Image Figure 25. Global Choroidal Neovascularization Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Choroidal Neovascularization Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Choroidal Neovascularization Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Choroidal Neovascularization Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Choroidal Neovascularization Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Choroidal Neovascularization Drug Sales Value Share by Application (2021-2032) Figure 31. Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Choroidal Neovascularization Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Choroidal Neovascularization Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Choroidal Neovascularization Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Choroidal Neovascularization Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Choroidal Neovascularization Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Choroidal Neovascularization Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Choroidal Neovascularization Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Choroidal Neovascularization Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Choroidal Neovascularization Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Choroidal Neovascularization Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Choroidal Neovascularization Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • EWA-001
  • Entolimod
  • DG-3
  • BBT-007
  • BB-3
  • AVMOC-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Soligenix, Inc.
  • RxBio, Inc.
  • RedHill Biopharma Ltd.
  • RDD Pharma Ltd.
  • ProCertus BioPharm Inc.
  • Pluristem Therapeutics Inc.
  • PharmaIN Corporation
  • Onconova Therapeutics, Inc.
  • Neumedicines Inc.
  • Meabco A/S
  • INSYS Therapeutics, Inc.
  • Humanetics Corporation
  • GNI Group Ltd.
  • Diffusion Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cellphire, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Choroidal Neovascularization Drug Sales Value (2021-2032)
  4. 1.2.2 Global Choroidal Neovascularization Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Choroidal Neovascularization Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Choroidal Neovascularization Drug Market Dynamics
  1. 2.1 Choroidal Neovascularization Drug Industry Trends
  2. 2.2 Choroidal Neovascularization Drug Industry Drivers
  3. 2.3 Choroidal Neovascularization Drug Industry Opportunities and Challenges
  4. 2.4 Choroidal Neovascularization Drug Industry Restraints
3 Choroidal Neovascularization Drug Market by Company
  1. 3.1 Global Choroidal Neovascularization Drug Company Revenue Ranking in 2025
  2. 3.2 Global Choroidal Neovascularization Drug Revenue by Company (2021-2026)
  3. 3.3 Global Choroidal Neovascularization Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Choroidal Neovascularization Drug Average Price by Company (2021-2026)
  5. 3.5 Global Choroidal Neovascularization Drug Company Ranking (2024-2026)
  6. 3.6 Global Choroidal Neovascularization Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Choroidal Neovascularization Drug Company Product Type and Application
  8. 3.8 Global Choroidal Neovascularization Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Choroidal Neovascularization Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Choroidal Neovascularization Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Choroidal Neovascularization Drug Market by Type
  1. 4.1 Choroidal Neovascularization Drug Type Introduction
  2. 4.1.1 EWA-001
  3. 4.1.2 Entolimod
  4. 4.1.3 DG-3
  5. 4.1.4 BBT-007
  6. 4.1.5 BB-3
  7. 4.1.6 AVMOC-001
  8. 4.1.7 Others
  9. 4.2 Global Choroidal Neovascularization Drug Sales Volume by Type
  10. 4.2.1 Global Choroidal Neovascularization Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Choroidal Neovascularization Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Choroidal Neovascularization Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Choroidal Neovascularization Drug Sales Value by Type
  14. 4.3.1 Global Choroidal Neovascularization Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Choroidal Neovascularization Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Choroidal Neovascularization Drug Sales Value Share by Type (2021-2032)
5 Choroidal Neovascularization Drug Market by Application
  1. 5.1 Choroidal Neovascularization Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Choroidal Neovascularization Drug Sales Volume by Application
  6. 5.2.1 Global Choroidal Neovascularization Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Choroidal Neovascularization Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Choroidal Neovascularization Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Choroidal Neovascularization Drug Sales Value by Application
  10. 5.3.1 Global Choroidal Neovascularization Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Choroidal Neovascularization Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Choroidal Neovascularization Drug Sales Value Share by Application (2021-2032)
6 Choroidal Neovascularization Drug Regional Sales and Value Analysis
  1. 6.1 Global Choroidal Neovascularization Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Choroidal Neovascularization Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Choroidal Neovascularization Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Choroidal Neovascularization Drug Sales by Region (2027-2032)
  5. 6.3 Global Choroidal Neovascularization Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Choroidal Neovascularization Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Choroidal Neovascularization Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Choroidal Neovascularization Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Choroidal Neovascularization Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Choroidal Neovascularization Drug Sales Value (2021-2032)
  12. 6.6.2 North America Choroidal Neovascularization Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Choroidal Neovascularization Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Choroidal Neovascularization Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Choroidal Neovascularization Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Choroidal Neovascularization Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Choroidal Neovascularization Drug Sales Value (2021-2032)
  21. 6.9.2 South America Choroidal Neovascularization Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Choroidal Neovascularization Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Choroidal Neovascularization Drug Sales Value Share by Country, 2025 VS 2032
7 Choroidal Neovascularization Drug Country-level Sales and Value Analysis
  1. 7.1 Global Choroidal Neovascularization Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Choroidal Neovascularization Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Choroidal Neovascularization Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Choroidal Neovascularization Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Choroidal Neovascularization Drug Sales by Country (2027-2032)
  6. 7.4 Global Choroidal Neovascularization Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Choroidal Neovascularization Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Choroidal Neovascularization Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Choroidal Neovascularization Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Choroidal Neovascularization Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Choroidal Neovascularization Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 Soligenix, Inc.
  8. 8.2.1 Soligenix, Inc. Company Information
  9. 8.2.2 Soligenix, Inc. Business Overview
  10. 8.2.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
  12. 8.2.5 Soligenix, Inc. Recent Developments
  13. 8.3 RxBio, Inc.
  14. 8.3.1 RxBio, Inc. Company Information
  15. 8.3.2 RxBio, Inc. Business Overview
  16. 8.3.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
  18. 8.3.5 RxBio, Inc. Recent Developments
  19. 8.4 RedHill Biopharma Ltd.
  20. 8.4.1 RedHill Biopharma Ltd. Company Information
  21. 8.4.2 RedHill Biopharma Ltd. Business Overview
  22. 8.4.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  24. 8.4.5 RedHill Biopharma Ltd. Recent Developments
  25. 8.5 RDD Pharma Ltd.
  26. 8.5.1 RDD Pharma Ltd. Company Information
  27. 8.5.2 RDD Pharma Ltd. Business Overview
  28. 8.5.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  30. 8.5.5 RDD Pharma Ltd. Recent Developments
  31. 8.6 ProCertus BioPharm Inc.
  32. 8.6.1 ProCertus BioPharm Inc. Company Information
  33. 8.6.2 ProCertus BioPharm Inc. Business Overview
  34. 8.6.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
  36. 8.6.5 ProCertus BioPharm Inc. Recent Developments
  37. 8.7 Pluristem Therapeutics Inc.
  38. 8.7.1 Pluristem Therapeutics Inc. Company Information
  39. 8.7.2 Pluristem Therapeutics Inc. Business Overview
  40. 8.7.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
  42. 8.7.5 Pluristem Therapeutics Inc. Recent Developments
  43. 8.8 PharmaIN Corporation
  44. 8.8.1 PharmaIN Corporation Company Information
  45. 8.8.2 PharmaIN Corporation Business Overview
  46. 8.8.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
  48. 8.8.5 PharmaIN Corporation Recent Developments
  49. 8.9 Onconova Therapeutics, Inc.
  50. 8.9.1 Onconova Therapeutics, Inc. Company Information
  51. 8.9.2 Onconova Therapeutics, Inc. Business Overview
  52. 8.9.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  54. 8.9.5 Onconova Therapeutics, Inc. Recent Developments
  55. 8.10 Neumedicines Inc.
  56. 8.10.1 Neumedicines Inc. Company Information
  57. 8.10.2 Neumedicines Inc. Business Overview
  58. 8.10.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
  60. 8.10.5 Neumedicines Inc. Recent Developments
  61. 8.11 Meabco A/S
  62. 8.11.1 Meabco A/S Company Information
  63. 8.11.2 Meabco A/S Business Overview
  64. 8.11.3 Meabco A/S Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
  66. 8.11.5 Meabco A/S Recent Developments
  67. 8.12 INSYS Therapeutics, Inc.
  68. 8.12.1 INSYS Therapeutics, Inc. Company Information
  69. 8.12.2 INSYS Therapeutics, Inc. Business Overview
  70. 8.12.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  72. 8.12.5 INSYS Therapeutics, Inc. Recent Developments
  73. 8.13 Humanetics Corporation
  74. 8.13.1 Humanetics Corporation Company Information
  75. 8.13.2 Humanetics Corporation Business Overview
  76. 8.13.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
  78. 8.13.5 Humanetics Corporation Recent Developments
  79. 8.14 GNI Group Ltd.
  80. 8.14.1 GNI Group Ltd. Company Information
  81. 8.14.2 GNI Group Ltd. Business Overview
  82. 8.14.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
  84. 8.14.5 GNI Group Ltd. Recent Developments
  85. 8.15 Diffusion Pharmaceuticals Inc.
  86. 8.15.1 Diffusion Pharmaceuticals Inc. Company Information
  87. 8.15.2 Diffusion Pharmaceuticals Inc. Business Overview
  88. 8.15.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
  90. 8.15.5 Diffusion Pharmaceuticals Inc. Recent Developments
  91. 8.16 Cumberland Pharmaceuticals, Inc.
  92. 8.16.1 Cumberland Pharmaceuticals, Inc. Company Information
  93. 8.16.2 Cumberland Pharmaceuticals, Inc. Business Overview
  94. 8.16.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
  96. 8.16.5 Cumberland Pharmaceuticals, Inc. Recent Developments
  97. 8.17 Cleveland BioLabs, Inc.
  98. 8.17.1 Cleveland BioLabs, Inc. Company Information
  99. 8.17.2 Cleveland BioLabs, Inc. Business Overview
  100. 8.17.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
  102. 8.17.5 Cleveland BioLabs, Inc. Recent Developments
  103. 8.18 Chrysalis BioTherapeutics, Inc.
  104. 8.18.1 Chrysalis BioTherapeutics, Inc. Company Information
  105. 8.18.2 Chrysalis BioTherapeutics, Inc. Business Overview
  106. 8.18.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  108. 8.18.5 Chrysalis BioTherapeutics, Inc. Recent Developments
  109. 8.19 Cellphire, Inc.
  110. 8.19.1 Cellphire, Inc. Company Information
  111. 8.19.2 Cellphire, Inc. Business Overview
  112. 8.19.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
  114. 8.19.5 Cellphire, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Choroidal Neovascularization Drug Value Chain Analysis
  2. 9.1.1 Choroidal Neovascularization Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Choroidal Neovascularization Drug Sales Mode & Process
  6. 9.2 Choroidal Neovascularization Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Choroidal Neovascularization Drug Distributors
  9. 9.2.3 Choroidal Neovascularization Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst